Wellington Management Group LLP Boosts Holdings in Altimmune, Inc. $ALT

Wellington Management Group LLP lifted its holdings in Altimmune, Inc. (NASDAQ:ALT) by 69.4% in the second quarter, HoldingsChannel reports. The fund owned 420,300 shares of the company’s stock after buying an additional 172,142 shares during the period. Wellington Management Group LLP’s holdings in Altimmune were worth $1,278,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in ALT. Arax Advisory Partners grew its holdings in shares of Altimmune by 99.7% during the 4th quarter. Arax Advisory Partners now owns 8,165 shares of the company’s stock valued at $29,000 after purchasing an additional 4,076 shares during the last quarter. Geneos Wealth Management Inc. purchased a new position in Altimmune in the 1st quarter worth $50,000. Victory Capital Management Inc. bought a new stake in Altimmune in the third quarter worth $38,000. BNP Paribas Financial Markets lifted its stake in Altimmune by 108.5% in the second quarter. BNP Paribas Financial Markets now owns 10,095 shares of the company’s stock worth $39,000 after purchasing an additional 5,253 shares during the last quarter. Finally, Quadrature Capital Ltd bought a new stake in Altimmune in the fourth quarter worth $36,000. 78.05% of the stock is currently owned by institutional investors.

Altimmune Trading Down 0.6%

NASDAQ:ALT opened at $3.27 on Friday. The firm has a market capitalization of $636.07 million, a P/E ratio of -4.19 and a beta of 0.18. The company has a quick ratio of 26.78, a current ratio of 26.78 and a debt-to-equity ratio of 0.07. The company has a fifty day moving average of $3.05 and a 200 day moving average of $3.15. Altimmune, Inc. has a 52 week low of $2.56 and a 52 week high of $6.44.

Altimmune (NASDAQ:ALT) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.02. Altimmune had a negative net margin of 214,860.98% and a negative return on equity of 31.41%. On average, research analysts predict that Altimmune, Inc. will post -0.58 earnings per share for the current year.

Analyst Upgrades and Downgrades

ALT has been the topic of a number of recent research reports. HC Wainwright reaffirmed a “buy” rating on shares of Altimmune in a research note on Tuesday, July 28th. Leerink Partners started coverage on Altimmune in a report on Monday, June 22nd. They issued an “outperform” rating and a $10.00 price objective on the stock. Wall Street Zen upgraded Altimmune from a “strong sell” rating to a “sell” rating in a report on Saturday, June 27th. Weiss Ratings restated a “sell (d-)” rating on shares of Altimmune in a report on Wednesday, June 24th. Finally, Citigroup restated a “market outperform” rating on shares of Altimmune in a research report on Tuesday, June 2nd. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Altimmune has a consensus rating of “Moderate Buy” and a consensus price target of $14.33.

Altimmune Profile

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.